Podcast Index
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
BioSpace
BioSpace
Grow In Grace
Pastor Ed Rae
Grow In Grace
Pastor Ed Rae
Worlo & Moons
SEN
A Felt Experience
Maria Cardozo
A Bit Fruity with Matt Bernstein
Matt Bernstein
On Air With Saaz
Sajana Giri
Isn't She Powerful | Stop Food Noise & Sugar Cravings
Laura Banks
You, me & the UPC
Bristows LLP
Do This, NOT That: Marketing Tips with Jay Schwedelson
GURU Media Hub
I'm Not A Lawyer But: The Debrief
Melanie Goolsby & Studio71
Lundin War Crimes Trial
PAX
The Saints
The Merry Beggars
أخبار بالعربي
SBS
Sleep Psalms with Bishop T.D. Jakes
Pray.com
Work Stress Anxiety | Burnout Prevention, Stress Recovery & Emotional Resilience for High-Achieving Women
Cheryl Paris | Work Stress & Burnout Specialist
Through the ESV New Testament in 90 Days with David Cochran Heath
Crossway
Through the ESV Bible in a Year with Jackie Hill Perry
Crossway
Chronological ESV Bible Plan with Robert Smith
Crossway
The M'Cheyne ESV Bible Plan with Kristyn Getty
Crossway
Morning and Evening TODAY
C. H. Spurgeon / W. C. Neff
Are you an artist?
Eline Peres
Refactoring Podcast
Luca Rossi
God Wants To Talk To You
God Wants To Talk To You
PROCLAIM x BIBLEin365
PROCLAIM x BIBLEin365
Wantrepreneur to Entrepreneur | Start and Grow Your Own Business
Brian Lofrumento
Dodger Blue Dream
iHeartPodcasts
Ready For Love with Hilary Silver
Cloud10
A Hora
UOL
Fear Daily
Brennan Storr & Brandon Schexnayder
Journal Intime - Témoignages de femmes ordinaires
Journal Intime - Témoignages de femmes
Two Inconvenient Women
ThoughtBox Education
The Unique Boutique Podcast
Matt Hodkinson
Real Life Ministry
Ryan Rice
The Poultry Network Podcast
Jake Davies
Neubauer Artists Happy Hour Show
Neubauer Artists LLC
Free Nights And Weekends
Scott
Tout
BioSpace
In this episode of Denatured, you’ll hear from Jack Crawford, CEO of Demetra, and Magnus Gustavsson, chief commercial officer at NorthX Biologics. We unpack the evolution of cell line development — CHO cells, targeted in...
A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for deriske...
The vibe at BIO 2026 in San Diego last week was overwhelmingly positive, with attendees observing noticeable changes at the FDA and an uptick in dealmaking and IPOs. Plus, a top medical journal this week retracted a pivo...
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll hear from Hakan Goker, managing director at M Ventures and Maina Bhaman, partner at Sofinnova Partners. We ex...
This year has been partly defined by a return to M&A. In the first quarter of 2026, biopharma spent nearly $47 billion in acquisitions across 19 deals, and this week, AbbVie notched another one for the second quarter, sc...
In this episode of Denatured, you'll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We examine how recessive dystrophic epidermolysis bullosa serve...
Moderna’s mRNA-based flu vaccine made headlines in February when the FDA declined to even review the application. Days later, the agency reversed course, setting a decision date for August and later scheduling an advisor...
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll hear from Hannah Franklin, associate at Biovance Capital and Pablo Gabriel Cironi Lopez, director of life sc...
Everything came up roses for Eli Lilly at the American Diabetes Association, as the pharma boasted positive results for its new pill Foundayo and next-gen asset retatrutide—not just for weight loss but also for other ind...
In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hai...
At the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this past weekend, packed plenary sessions from Revolution Medicines and Summit Therapeutics’ Chinese partner Akeso stole the show. For RevMed...
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, m...
Eli Lilly has been as acquisitive as ever, striking five new deals in the past week alone. On Tuesday, the company dove into the deep end of vaccine development with three separate buys in the space. Outside of vaccines,...
In this episode of Denatured, as part of our series of the European life science investment ecosystem, you'll be hearing from Regina Hodits, managing director at Angelini Ventures and Sofia Ioannidou, VC partner at Ande...
FDA Commissioner Marty Makary officially resigned last week following reports of his ouster. Then, the acting directors for the agency’s two main review units also left their posts, as did the FDA chief of staff and chie...
In this episode of Denatured, you'll be hearing from Miguel Forte, president of the International Society for Cell and Gene Therapy (ISCT), and John Ellis, co-founder & CEO of Trenchant Bios, speaking live from the ISCT ...
Moments after recording this episode of The Weekly, FDA Commissioner Marty Makary announced his resignation. Reports first circulated last Friday that President Donald Trump had signed off on his ouster. The president in...
In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder & Chief Medical Officer of Calluna Pharma. We dive into IPF and fibrosis challenges, unpackin...
First quarter earnings continue to roll in, with Pfizer, Eli Lilly, Amgen and more reporting in the past week. While Pfizer beat consensus estimates, it wasn’t enough for analysts, who had greater expectations for the Ne...
First quarter earnings continue to roll in, with Pfizer, Eli Lilly, Amgen and more reporting in the past week. While Pfizer beat consensus estimates, it wasn’t enough for analysts, who had greater expectations for the Ne...
Remplissez le formulaire ci-dessous. Veillez à sélectionner à la fois Pays et Genres.
Envoyez-nous un message ci-dessous. Nous vous répondrons dans les 24 heures.